

December 23, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Corporate Officer

TOKYO, December 23, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo) today announced the approval of the appointment of corporate officers by the Board of Directors at a meeting of the board held on December 17, 2020.

1. Appointment of Corporate Officers

The Company is enhancing its organizational structure for implementation of the mid-range plan. Full operation of the Company's own sales organization commenced on December 10, 2020, and to further strengthen corporate functions to achieve profitability in 2021 and to transition into a global business, the following three new corporate officers will be appointed effective from January 1, 2021.

Statement from Mr. Fuminori Yoshida, SymBio's President and CEO: "As the Company expands its business toward its second inauguration, we have established a nationwide sales and distribution system to further strengthen the stable supply of products and quality assurance. In anticipation of the start of the global phase II study of Brincidofovir, we will appoint three corporate officers managing major business divisions to enhance management structure and further solidify the growth trajectory."

(1) Newly Appointed Corporate Officer

Name	Title
Masayuki Aboshi	Corporate Officer Head of Research and Development Division
Yoshiharu Torikai	Corporate Officer Head of Regulatory Affairs and Quality Assurance Division
Kozo Yoshida	Corporate Officer Head of Sales Division, Japan Business Unit

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125